The Column Group
The Column Group is a venture capital firm dedicated to developing biotechnology companies.
Business Model:
Revenue: $45M
Employees: 51-200
Rankings
Detailed The Column Group Information
Geographic Data
Address: 1700 Owens St
City: San Francisco
State: CA
Zip: 94158
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$1B
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
The Column Group is a leading venture capital firm dedicated to creating the next generation of biotechnology companies
Contact Phone:
+14158652050
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 11/2017 | Arcus Biosciences | Series C | 107M |
| 4/2020 | Accent Therapeutics | Series B | 0 |
| 1/2022 | Eikon Therapeutics | Series B | 0 |
| 11/2017 | Exonics Therapeutics | Series A | 40M |
| 1/2021 | Plexium | Series A | 35M |
| 2/2018 | ProNeurotech | Venture Round | - |
| 12/2018 | Kallyope | Series B | 21M |
| 6/2010 | Constellation Pharmaceuticals | Series B | 22.3M |
| 12/2016 | Revolution Medicines | Series A | 25M |
| 6/2011 | Constellation Pharmaceuticals | Series B | 15M |
| 7/2017 | Constellation Pharmaceuticals | Series E | 48.5M |
| 11/2022 | Escient Pharmaceuticals | Series C | 120M |
| 9/2020 | Synthekine | Series A | 82M |
| 1/2019 | Remix Therapeutics | Seed Round | 16M |
| 11/2014 | ORIC Pharmaceuticals | Series A | 15M |
| 9/2016 | Arcus Biosciences | Series B | 70M |
| 1/2009 | Igenica | Series A | 3.1M |
| 10/2020 | A2 Biotherapeutics | Series B | 71.5M |
| 6/2011 | Cyterix Pharmaceuticals | Series A | 9.2M |
| 9/2020 | Carmot Therapeutics | Series C | 47M |
| 7/2020 | Nura Bio | Series A | 73M |
| 9/2020 | Casma Therapeutics | Series B | 50M |
| 3/2020 | Kallyope | Series C | 112M |
| 12/2015 | Kallyope | Series A | 44M |
| 10/2015 | Gritstone Bio | Series A | 102M |
| 5/2022 | Remix Therapeutics | Series B | 0 |
| 6/2010 | Igenica | Series B | 24M |
| 5/2021 | Eikon Therapeutics | Series A | 148M |
| 3/2020 | Nurix Therapeutics | Private Equity Round | 120M |
| 3/2019 | Surrozen | Series B | 50M |
| 6/2020 | Surrozen | Series C | 50M |
| 1/2023 | Synthekine | Series C | 100M |
| 3/2021 | Tenaya Therapeutics | Series C | 106M |
| 12/2015 | ORIC Pharmaceuticals | Series B | 53M |
| 1/2018 | Carmot Therapeutics | Series B | 15M |
| 12/2020 | Remix Therapeutics | Series A | 65M |
| 2/2018 | ORIC Pharmaceuticals | Series C | 50M |
| 12/2014 | Flexus Biosciences | Series B | 38M |
| 6/2012 | Igenica | Series C | 33M |
| 7/2009 | Sagimet Biosciences | Series B | 30M |
| 11/2011 | NGM Biopharmaceuticals | Series B | 55.4M |
| 10/2013 | Immune Design | Series C | 49M |
| 8/2021 | Surrozen | Post-IPO Equity | 0 |
| 10/2013 | Seragon Pharmaceuticals | Series A | 30M |
| 4/2010 | Aragon Pharmaceuticals, Inc. | Series B | 22M |
| 5/2009 | Aragon Pharmaceuticals, Inc. | Series A | 8M |
| 8/2009 | Constellation Pharmaceuticals | Series A | 17.2M |
| 11/2019 | A2 Biotherapeutics | Series A | 57M |
| 5/2018 | Accent Therapeutics | Series A | 40M |
| 12/2015 | Ribon Therapeutics | Venture Round | 10M |
| 11/2022 | Cajal Neuroscience | Series A | 96M |
| 7/2011 | Peloton Therapeutics | Series A | 18M |
| 5/2014 | Nurix Therapeutics | Series B | 25.1M |
| 9/2020 | Hexagon Bio | Series A | 47M |
| 12/2016 | Tenaya Therapeutics | Series A | 50M |
| 2/2016 | Ribon Therapeutics | Series A | 24M |
| 12/2015 | Neurona Therapeutics | Series A | 23.5M |
| 12/2009 | PTC Therapeutics | Venture Round | 50M |
| 11/2022 | Casma Therapeutics | Series C | 46M |
| 12/2017 | Rapt Therapeutics | Series C | 60M |
| 2/2019 | Peloton Therapeutics | Series E | 0 |
| 8/2021 | Atavistik Bio | Series A | 60M |
| 6/2021 | Circle Pharma | Series C | 0 |
| 5/2012 | Nurix Therapeutics | Seed Round | 3.1M |
| 10/2012 | Aragon Pharmaceuticals, Inc. | Series D | 50M |
| 9/2020 | Escient Pharmaceuticals | Series B | 77.5M |
| 12/2015 | Constellation Pharmaceuticals | Series E | 55M |
| 3/2013 | Nurix Therapeutics | Venture Round | 5.3M |
| 1/2014 | Igenica | Series C | 14M |
| 4/2008 | Constellation Pharmaceuticals | Series A | 32M |
| 6/2021 | Neurona Therapeutics | Venture Round | 0 |
| 10/2019 | Plexium | Series A | 28M |
| 5/2018 | Escient Pharmaceuticals | Series A | 40M |
| 7/2008 | Immune Design | Series A | 18M |
| 12/2015 | Effector Therapeutics | Series B | 40M |
| 1/2019 | Ribon Therapeutics | Series B | 65M |
| 2/2022 | Kallyope | Series D | 0 |
| 9/2021 | Obsidian Therapeutics | Series B | 0 |
| 8/2021 | Effector Therapeutics | Post-IPO Equity | 0 |
| 7/2010 | Immune Design | Series B | 32M |
| 10/2019 | Constellation Pharmaceuticals | Post-IPO Equity | 65M |
| 7/2017 | Effector Therapeutics | Series C | 38.6M |
| 9/2017 | Gritstone Bio | Series B | 93M |
| 6/2019 | Rapt Therapeutics | Series C | 0 |
| 8/2019 | ORIC Pharmaceuticals | Series D | 0 |
| 10/2019 | Tenaya Therapeutics | Series B | 92M |
| 6/2021 | Synthekine | Series B | 0 |
| 3/2015 | NGM Biopharmaceuticals | Series D | 57.5M |
| 4/2018 | Constellation Pharmaceuticals | Series F | 0 |
| 6/2021 | Ribon Therapeutics | Series C | 0 |
| 3/2020 | Circle Pharma | Series B | 0 |
| 9/2016 | Peloton Therapeutics | Series D | 0 |
| 4/2018 | Revolution Medicines | Series B | 56M |
| 9/2021 | Hexagon Bio | Series B | 61M |
| 10/2022 | Hexagon Bio | Series B | 0 |
| 2/2022 | Plexium | Series B | 0 |
| 4/2016 | Rapt Therapeutics | Series B | 0 |
| 5/2015 | Arcus Biosciences | Series A | 49.7M |
| 2/2018 | Kallyope | Series B | 66M |
| 5/2023 | Carmot Therapeutics | Series E | 0 |
| 12/2009 | NGM Biopharmaceuticals | Series A | 26.6M |
| 7/2022 | Carmot Therapeutics | Series D | 0 |
| 4/2010 | Carmot Therapeutics | Series A | 1.5M |
| 7/2012 | Carmot Therapeutics | Venture Round | 500.2k |
| 7/2019 | Revolution Medicines | Series C | 100M |
| 2/2017 | Surrozen | Series A | 33M |
| 7/2022 | Carmot Therapeutics | Series D | 0 |
| 5/2022 | Remix Therapeutics | Series B | 0 |
| 2/2022 | Plexium | Series B | 0 |
| 2/2022 | Kallyope | Series D | 0 |
| 1/2022 | Eikon Therapeutics | Series B | 0 |
| 9/2021 | Hexagon Bio | Series B | 0 |
| 9/2021 | Obsidian Therapeutics | Series B | 0 |
| 8/2021 | Effector Therapeutics | Post-IPO Equity | 0 |
| 8/2021 | Atavistik Bio | Series A | 0 |
| 8/2021 | Surrozen | Post-IPO Equity | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
